logo
  

Jazz Pharma Updates 2021 Outlook To Include Recently Acquired GW Pharma

Jazz Pharmaceuticals plc (JAZZ) updated its full year 2021 financial guidance to incorporate the GW Pharmaceuticals business, which the company acquired on May 5, 2021.

For 2021, the company now expects GAAP loss per share to be in the range of $2.00 - $4.70, non-GAAP net income per share of $13.40 - $14.70, and revenues of $3.02 billion - $3.18 billion. Analysts polled by Thomson Reuters expect the company to report earnings of $15.05 per share and revenues of $3.11 billion for fiscal year 2021. Analysts' estimates typically exclude special items.

Previously, the company had expected annual earnings per share to be in the range of $8.30 - $10.45, non-GAAP net income of $15.65 - $16.85, and revenues of $2.55 billion - $2.70 billion.

The company expects the GW transaction to be dilutive to both GAAP and non-GAAP adjusted net income per diluted share in 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT